Affimed N V's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Affimed N V (AFMD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Affimed N V vs Its Competitors
- TTM: Trailing 12-month revenue of 9M vs 687,133M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months), vs accelerating (+45.5%) for its tracked peer group.
- Growth: Affimed N V generated -80.0% revenue growth year over year in Q4 2023, vs -0.3% for its competitors combined.
- Profitability: Its -1,280.2% net margin compares with 14.7% for the peer group.
- Peer revenue share: Affimed N V accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.09M compares with $1.02M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AFMD Sales vs. its Competitors, Q4 2023
Affimed N V reported revenue contraction of 79.99 % year on year in Q4 2023, below its competitors' combined revenue change of -0.34 %.
With a net margin of -1,280.22 %, Affimed N V reported lower profitability than its competitors (14.69 %).
Affimed N V generated 0.00 % of the combined sales of its peer group, down from 0.02 % a year earlier.
API endpoints for this dataset
Affimed N V vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Affimed N V reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Affimed N V and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Affimed N v | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Affimed N V's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -80.0% for Affimed N V. Affimed N V's share of combined industry revenue moved from 0.01% to 0.00%, a loss of 0.01 percentage points.
Affimed N V's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Affimed N v | - | No | No | Yes |
| Competitors combined (208) | ||||
| High-Confidence Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AFMD Stock Performance relative to its Competitors
AFMD Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inmed Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Gt Biopharma Inc | 282.9% | Outperformed |
| 3 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 4 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 5 | Erasca Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Affimed N V's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Affimed N V's Comment on Competition and Industry Peers
Publicly Traded Peers of Affimed N v
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Affimed N v |
2.76 | 8.95 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
| SUBTOTAL | 4,640,887.20 | 720,150.84 |
Sign in to see all competitors of Affimed N v .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Affimed N v versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Affimed N V's Competitors Named by the Company
Competitive relationships identified from Affimed N V reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Aptevo Therapeutics Inc | Company report | 85% |
| ADAPTIN BIO, INC. | Company report | 85% |
| Nkgen Biotech Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Merus N v | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Immunogen inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Affimed N V's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Affimed N V's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Affimed N V's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Affimed N v | 3 | 87,752 | -1,123,422 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| PEERS TOTAL | 4,640,884 | 1,018,738 | 148,769 |
Affimed N V's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Affimed N V's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Affimed N V's industry classification, broader than the peer set above. Market cap in millions of $.Affimed N V ranks #0 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Affimed N v | - | 0.00 % |
Market cap and industry share for the rest of Affimed N V's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-15.
Affimed N V's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.89 % (avg) | -37.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.23 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 45.06 % | 7.58 % (avg) | +37.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Affimed N V's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | 47.57 % | -8.78 % | -79.45 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -22.59 % | -28.37 % | -89.10 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Affimed N V's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 45.06 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Affimed N V's dedicated Suppliers and Customers pages, not here.
Affimed N V's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months).
Weaknesses
- Return on equity 190.2 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (57.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Affimed N V's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Affimed N v | 1.49 | 3.25 | 0.11 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Affimed N V's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Affimed N v | Q4 2023 | -79.5 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +10.4 % | +6.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Affimed N V's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Affimed N v | Q4 2023 | - | +481.0 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Affimed N V's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Affimed N v | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Affimed N V's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Affimed N v | - | 0.31 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Johnson and Johnson | 41.79 | 6.81 |
| Abbvie Inc | 50.14 | 7.82 |
| Merck and Co Inc | 118.32 | 5.44 |
| Novartis Ag | 22.73 | 5.61 |
| PEERS AVERAGE | 44.18 | 6.44 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.